Question 1

What is the primary endpoint of the POETYK PsA-2 study?

Accepted Answer

The primary endpoint is ACR20 response at week 16.

Question 2

Which patients were included in this trial?

Accepted Answer

Adults with active PsA meeting CASPAR criteria, with active arthritis, a documented plaque psoriasis history, and hsCRP ≥ 3 mg/L at screening were included, including those naive to biologic DMARDs/TNFi or with up to two prior TNFi failures or intolerance.

Question 3

How were treatments assigned and handled after week 16?

Accepted Answer

Patients were randomized 3:3:1 to deucravacitinib 6 mg once daily, placebo, or apremilast 30 mg twice daily through week 16; from weeks 16 to 52, deucravacitinib/apremilast continued while placebo patients switched to deucravacitinib, and safety was evaluated through week 52.